Stockscreener 앱 받기
2.03
6.28%
0.12
시간 외 거래:
2.03
Biomea Fusion Inc 주식(BMEA)의 최신 뉴스
After Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is Bright - Yahoo Finance
Biomea Fusion Completes Key Phase 2 Trial in Type 1 Diabetes: What Investors Should Watch Next - TipRanks
Biomea Fusion to Participate in Upcoming Investor Conferences - investingnews.com
BMEA Surges 6.85%: Biomea Fusion Approaches Key $1.88 ResistanceQuote Data - vinanet.vn
BMEA Should I Buy - Intellectia AI
Biomea Fusion Inc (BMEA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - tradingkey.com
Biomea Shares Rise After Completing Enrollment in Diabetes Trial - marketscreener.com
Biomea Fusion stock surges on diabetes trial enrollment completion By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Biomea Fusion stock rating on trial enrollment By Investing.com - Investing.com UK
Why is Biomea Fusion stock climbing today? By Investing.com - Investing.com India
Biomea Fusion Announces Completion Of Enrollment In Covalent-211 Phase Ii Trial Of Icovamenib In Insulin-Deficient Type 2 Diabetes - TradingView
Biomea Fusion completes enrollment in diabetes trial By Investing.com - Investing.com UK
Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it? - TradingView
Biomea Fusion completes enrollment in diabetes trial - Investing.com
Biomea (BMEA) Quarterly Results: Profit Per Share Clears Its Benchmark at the Close; Investor Response - vinanet.vn
Biomea Fusion begins dosing first participant in OPAL study arm for new combination therapy - Traders Union
Biomea Fusion (NASDAQ:BMEA) Gains Attention As Institutions Expand Exposure - Kalkine Media
Biomea Fusion shares new insights on three stages of type 1 diabetes in expert webinar - Traders Union
Biomea Fusion doses first patient in icovamenib-semaglutide study By Investing.com - Investing.com Canada
Biomea Fusion doses first patient in icovamenib-semaglutide study - Investing.com
Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity - The Manila Times
Biomea Fusion Initiates OPAL Study Arm of Icovamenib Plus Low-Dose Semaglutide in Obesity Research - Quiver Quantitative
Biomea Fusion Trial Tests Obesity Drug Combo Beyond Weight Loss - Stock Titan
Renaissance Technologies LLC Grows Position in Biomea Fusion, Inc. $BMEA - MarketBeat
Biomea Fusion Inc (BMEA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BMEA Q2 2026 Earnings: Narrower Loss Delivers 47% EPS Surprise as Pipeline Progress ContinuesEarnings Outlook Update - vinanet.vn
HC Wainwright Expects Stronger Earnings for Biomea Fusion - MarketBeat
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Biomea Fusion Stock (BMEA) Opinions on Clinical Milestones and Liquidity Concerns - Quiver Quantitative
Icovamenib clinical enrollment opens for type 2 diabetes study, Biomea Fusion initiates - Traders Union
Piper Sandler Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Citizens JMP Maintains Biomea Fusion(BMEA.US) With Buy Rating, Cuts Target Price to $7 - Moomoo
Biomea Fusion Inc (BMEA) Stock News Today - TradingKey
Biomea Fusion explores new scientific approaches to diabetes treatment - Traders Union
Oppenheimer Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Biomea Fusion (BMEA) Edges Higher: Bounces Off Support as Oversold Conditions EaseIndex Put Call - dars.gov.et
Biomea Fusion, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Biomea Fusion (NASDAQ:BMEA) Issues Earnings Results - MarketBeat
Biomea Fusion Q2 loss narrows, cash runway into Q2 2027 - TradingView
Biomea Fusion (NASDAQ: BMEA) trims R&D, discloses going concern risk - Stock Titan
Biomea Fusion, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights - Yahoo Finance
Biomea Fusion (BMEA) Gains 2.56% to $1.2 as Key Levels Come into FocusStock Surge Alerts - dars.gov.et
Participants sought for type 2 diabetes trial evaluating icovamenib, Biomea Fusion announces - Traders Union
Biomea Fusion Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
BMEA Q2'26 Earnings: EPS estimate is (0.22) USD - tradingview.com
Biomea Fusion (BMEA) Nears Key Support as Selling Pressure ContinuesMA Crossover - vinanet.vn
Biomea Fusion (BMEA) to Post Earnings on Tuesday - MarketBeat
Biomea Fusion Inc (BMEA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Biomea Fusion Inc (BMEA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BMEA|Biomea Fusion Inc|Price:1.250|Chg%:-0.010 - TradingKey
Biomea Fusion Inc (BMEA) Balance Sheet - TradingKey
Biomea Fusion Inc (BMEA) Income Statement - TradingKey
Biomea Fusion Inc (BMEA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Biomea Fusion Inc (BMEA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BMEA|Biomea Fusion Inc|Price:1.265|Chg%:+0.015 - TradingKey
BMEA Q2'26 Earnings: revenue estimate is 0 USD - TradingView
TradingKey - TradingKey
Biomea Fusion Inc (BMEA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Biomea Fusion Inc (BMEA) Institutional Confidence - TradingKey
0.86%
0.31%
자본화:
|
볼륨(24시간):